Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M Wheeler

Showing results (111-120 of 143) with videos related to

Pageof 15
Sort By:
Investigational New Drugs|April 24, 2013
HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancerGuru Sonpavde, Mingjun Wang, Leif E Peterson, et al.
American Journal of Clinical Pathology|June 21, 2011
Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcomeKenneth A Iczkowski, Kathleen C Torkko, Gregory R Kotnis, et al.
The American Journal of Surgical Pathology|August 30, 2008
Grading of invasive cribriform carcinoma on prostate needle biopsy: an interobserver study among experts in genitourinary pathologyMathieu Latour, Mahul B Amin, Athanase Billis, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 31, 2010
International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced diseaseCristina Magi-Galluzzi, Andrew J Evans, Brett Delahunt, et al.
The American Journal of Pathology|January 13, 2011
Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimensGustavo E Ayala, Bahar Muezzinoglu, Kai H Hammerich, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 17, 2006
Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancerGustavo Ayala, Takefumi Satoh, Rile Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement?Ilias Cagiannos, Markus Graefen, Pierre I Karakiewicz, et al.
The Journal of Urology|May 19, 2010
Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancerLionel L Bañez, Leon Sun, Geert J van Leenders, et al.
Health Affairs Scholar|May 17, 2024
Re-evaluation of the methodology for estimating the US specialty physician workforceW Stephen Black-Schaffer, David J Gross, Zakia Nouri, et al.
Archives of Pathology & Laboratory Medicine|October 2, 2009
Protocol for the examination of specimens from patients with carcinoma of the prostate glandJohn R Srigley, Peter A Humphrey, Mahul B Amin, et al.
Pageof 15

Showing results (111-120 of 143) with videos related to

Sort By:
Pageof 15
Investigational New Drugs|April 24, 2013
HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancerGuru Sonpavde, Mingjun Wang, Leif E Peterson, et al.
American Journal of Clinical Pathology|June 21, 2011
Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcomeKenneth A Iczkowski, Kathleen C Torkko, Gregory R Kotnis, et al.
The American Journal of Surgical Pathology|August 30, 2008
Grading of invasive cribriform carcinoma on prostate needle biopsy: an interobserver study among experts in genitourinary pathologyMathieu Latour, Mahul B Amin, Athanase Billis, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 31, 2010
International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced diseaseCristina Magi-Galluzzi, Andrew J Evans, Brett Delahunt, et al.
The American Journal of Pathology|January 13, 2011
Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimensGustavo E Ayala, Bahar Muezzinoglu, Kai H Hammerich, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 17, 2006
Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancerGustavo Ayala, Takefumi Satoh, Rile Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement?Ilias Cagiannos, Markus Graefen, Pierre I Karakiewicz, et al.
The Journal of Urology|May 19, 2010
Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancerLionel L Bañez, Leon Sun, Geert J van Leenders, et al.
Health Affairs Scholar|May 17, 2024
Re-evaluation of the methodology for estimating the US specialty physician workforceW Stephen Black-Schaffer, David J Gross, Zakia Nouri, et al.
Archives of Pathology & Laboratory Medicine|October 2, 2009
Protocol for the examination of specimens from patients with carcinoma of the prostate glandJohn R Srigley, Peter A Humphrey, Mahul B Amin, et al.
Pageof 15